Studies have shown that active fund managers routinely underperform the S&P500 index*​

First Tracks Biotherapeutics, Inc. (NASDAQ: TRAX)

TRAX Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
161.10%

TRAX Stock Analysis

TRAX PE Ratio:

TRAX PEG Ratio: Not Available

TRAX Forward EPS Growth (12 month): 0.00%

TRAX PS Ratio:

TRAX PSG Ratio: Not Available

TRAX Forward Revenue Growth (12 month): 0.00%

TRAX Articles

No data was found